Silence Therapeutics said its CEO Mark Rothera resigned from the company and stepped down from the board as it has named Craig Tooman, the company’s CFO, as president, CEO, and a board member.
Photo: Craig Tooman, CEO of Silence Therapeutics
Rhonda Hellums, previously vice president of finance, has been appointed CFO.
“Craig is a seasoned leader who understands all aspects of our corporate strategy and the immediate need to maximize our potential going forward,” said Iain Ross, chairman at Silence. “With Craig as CEO and Dr. Giles Campion leading our exceptional research and development efforts, I am confident that Silence is now well-positioned to capitalize appropriately on the positive data we recently reported with SLN360 and ensure long-term shareholder value.”
Tooman joined Silence in January 2021, and brings more than 30 years of operational, financial and merger and acquisition experience. Most recently, he was Chief Operating Officer and CFO at Vyome Therapeutics. Prior to that, he was CEO of Aratana Therapeutics where he successfully negotiated a merger with Elanco. Before Aratana, Tooman was the CEO of Avanzar Medical, a private oncology company, and CFO of Enzon Pharmaceuticals until its acquisition by Sigma Tau.
Prior to that he led the $1.1 billion M&A initiative and integration of ILEX Oncology and Genzyme Corporation. He also held key positions at Pharmacia and Upjohn. Tooman currently serves on the supervisory board and audit committee of CureVac, which accomplished a successful initial public offering on Nasdaq in August of 2020. He holds a B.A. in economics from Kalamazoo College and an MBA from the University of Chicago.
Author: Rare Daily Staff
Stay Connected
Sign up for updates straight to your inbox.